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P-glycoproteinCanine lymphoma is routinely treated with a doxorubicin-based multidrug chemotherapy protocol, and
although treatment is initially successful, tumor recurrence is common and associated with therapy
resistance. Active efﬂux of chemotherapeutic agents by transporter proteins of the ATP-Binding Cassette
superfamily forms an effective cellular defense mechanism and a high expression of these transporters is
frequently observed in chemotherapy-resistant tumors in both humans and dogs.
In this study we describe the ABC-transporter expression in a canine lymphoid cell line and a sub-cell
line with acquired drug resistance following prolonged exposure to doxorubicin. This sub-cell line was
more resistant to doxorubicin and vincristine, but not to prednisolone, and had a highly increased
P-glycoprotein (P-gp/abcb1) expression and transport capacity for the P-gp model-substrate
rhodamine123. Both resistance to doxorubicin and vincristine, and rhodamine123 transport capacity
were fully reversed by the P-gp inhibitor PSC833. No changes were observed in the expression and
function of the ABC-transporters MRP-1 and BCRP.
It is concluded that GL-40 cells represent a useful model for studying P-gp dependent drug resistance in
canine lymphoid neoplasia, and that this model can be used for screening substances as potential P-gp
substrates and their capacity to modulate P-gp mediated drug resistance.
 2014 Elsevier Ltd. All rights reserved.1. Introduction treatment with glucocorticoids prior to starting chemotherapyCanine lymphoma (cL), the most common hematopoietic neo-
plasia in the dog, is in many respects comparable to non-Hodgkin
lymphoma in humans (Teske, 1994). As in humans, treatment in
the dog consists of a multidrug chemotherapy protocol that
includes, as a minimum, cyclophosphamide, doxorubicin, vincris-
tine and prednisolone (or CHOP-protocol) (Garrett et al., 2002;
Sorenmo et al., 2010) of which, as a single agent, doxorubicin
appears most effective (Simon et al., 2008). Despite a high initial
response rate, tumor relapse is common and more often refractory
to therapy, leading to treatment failure and ultimately the dog’s
death (Flory et al., 2011; Zandvliet et al., 2013). The main cause
for treatment failure is thought to be tumor drug resistance (DR)
that can be present at the start of chemotherapy (intrinsic DR) or
develop during or following chemotherapy (acquired DR). Several
clinical studies on cL (Price et al., 1991; Piek et al., 1999;
Gavazza et al., 2008; Marconato et al., 2011) have documented thatlowers the overall response rate and shortens survival and this
has been explained by assuming acquired, glucocorticoid-induced
DR (Mealey et al., 2003).
One of the mechanisms underlying DR is the active efﬂux of
(cytotoxic) drugs by membrane bound transporter proteins of the
ATP-Binding Cassette (ABC) superfamily (Gottesman, 2002;
Huang et al., 2004). High expression of these ABC-transporters,
and P-glycoprotein (P-gp; ABCB1) in particular, has been associ-
ated with both a decreased sensitivity to cytotoxic agents, as well
as a poor prognosis in several types of cancer in humans (Huang
et al., 2004; Gottesman et al., 2002; Kourti et al., 2007; Efferth
et al., 2008) and dogs (Bergman et al., 1996; Lee et al., 1996;
Steingold et al., 1998; Honscha et al., 2009). Other ABC-transporters
associated with DR to cytotoxic agents in humans include multi-
drug resistance related protein 1 (MRP1; ABCC1) and breast cancer
resistance protein (BCRP; ABCG2) (Gillet et al., 2007), both of
which have been studied in veterinary medicine (Honscha et al.,
2009; Tashbaeva et al., 2007; Schrickx and Fink-Gremmels, 2008;
Mealey, 2012), but not in relation to cL.
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agement of cancer with chemotherapy in both humans and dogs,
therapeutic measures to circumvent DR are still limited (Szakacs
et al., 2006). Studying the mechanisms responsible for DR will
provide a better understanding of DR (Chen and Sikic, 2012) and
could potentially lead to the development of new therapies
(Efferth et al., 2008; Zhu et al., 2009). For the dog both these goals
would be greatly facilitated with a canine in vitro model, but a
previously reported DR cell line (Uozurmi et al., 2005) derived from
the canine lymphoid GL-1 cell line (Nakaichi et al., 1996) is no
longer available.
The ﬁrst goal of the current study was to re-establish a DR
canine lymphoid cell line through selection for doxorubicin-
resistance. Doxorubicin was purposefully chosen given its’ efﬁcacy
in the treatment of cL, but also because resistance to doxorubicin is
predictive for multidrug resistance in human neoplasia (Efferth
et al., 2008). The second goal was to assess in both the original
and the doxorubicin resistant sub-cell line, the antiproliferative
effect of the drugs used in a CHOP-protocol, and the expression
and function of the ABC-transporters P-gp, MRP1 and BCRP in both
cell lines.2. Material and methods
2.1. Chemicals
PSC833 (Valspodar) was a gift from Novartis Pharma AG
(Basel, Switzerland) and Ko143 was kindly provided by Prof.
Koomen (University of Amsterdam, the Netherlands). MK571
sodium salt was obtained from Alexis Biochemicals (Grünberg,
Germany). Rhodamine 123 (Rh123), and 5(6)-carboxyﬂuorescein
diacetate (CFDA) were purchased from Sigma–Aldrich (St Louis,
MO, USA). Pheophorbide A (PhA) was obtained from Frontier
Scientiﬁc (Logan, USA). Doxorubicin hydrochloride and vincristine
sulfate and prednisolone were purchased from Sigma–Aldrich
(St Louis, MO, USA).
2.2. Cell lines, cell culture media and supplements
The canine lymphoid cell-line, GL-1 cells (Nakaichi et al., 1996),
was kindly provided by dr K. Ohno (University of Tokyo). The cells
were conﬁrmed to be of canine origin through DNA-sequencing
(four regions, 900 base-pairs in total) and showed 100% homology
with the canine reference genome. GL-1 cells grow in single cell
suspension and showed strong immunoreactivity with CD34 and
CD79a, a weak reaction with CD3 and CD4 and no reaction with
CD21 and CD90, consistent with a precursor lymphoid cell of the
B-lineage.
GL-1 cells were grown in suspension on RPMI 1640 (Gibco,
Grand Island, NY, USA) supplemented with 1% (v/v) L-glutamine
(BioWhittaker, Maine, USA), 10% (v/v) fetal bovine serum (Gibco)
and 100 U/mL penicillin and 100 lg/ml streptomycin (BioWhittaker)
at 37 C, 5% CO2. The GL-1 cells were cultured with gradually
increasing concentrations of doxorubicin and after 6 months a
subline of the GL-1 cells was selected that could be cultured in
the presence of 0.07 lM (40 ng/mL, hence GL-40) doxorubicin.
Multiple batches of these GL-40 cells were stored in liquid nitrogen
and were maintained in culture after thawing following a schedule
of one passage with doxorubicin (20 ng/mL) and two passages
without doxorubicin
2.3. Proliferation assay
Cell proliferation was assessed with the Cell Counting Kit-8
assay (CCK-8, Dojindo Molecular Technologies, Rockville,Maryland, USA) using the tetrazolium salt, WST-8 (2-(2-meth-
oxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt), which produces a water-soluble
formazan dye following bioreduction in the presence of the
electron carrier, 1-methoxy PMS. Cells were seeded in 96-well
plates at a density of 2  104 cells per well in cell culture medium
containing a concentration range of doxorubicin, vincristine or
prednisolone and incubated for 24, 47, and 72 h at 37 C, 5% CO2.
The tetrazolium solution was added to each well 2½ h before light
absorbance analysis. The formation of the soluble formazan was
measured by light absorbance at 450 nm in a microplate reader.
Cell proliferation was calculated by dividing the light absorbance
in treated cells by that in control cells after correction for back-
ground absorbance.
Concentration dependent effects were analyzed by non-linear
regression after log transformation of the concentration and graphs
were ﬁtted according to a sigmoïd dose–response curve. A time-
dependent effect was observed on GL-cell proliferation and results
were reported after 72 h of incubation.
2.4. RNA isolation and synthesis of cDNA
Total RNA was isolated using the SV-total RNA isolation kit
(Promega, Leiden, The Netherlands) according to the manufac-
turer’s protocol including a DNAse treatment. The RNA was
quantiﬁed spectrophotometrically at 260 nm (ND-1000, Nanodrop
technologies) and stored at 70 C.
First strand cDNA from 1 lg total RNA was synthesized with the
iScript™ cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA) contain-
ing both oligo (dT) and random hexamer primers in a ﬁnal volume
of 20 lL according the manufacture’s recommendation. The cDNA
was stored at 20 C.
2.5. Real time quantitative PCR analysis
Gene-speciﬁc primers were developed, commercially synthe-
sized (Eurogentec, Maastricht, the Netherlands) and tested for efﬁ-
ciency by using a dilution series of cDNA. The efﬁciency of the
primers was between 95% and 105% and only one product was
formed as assessed by melting curve analysis. 50 ng reverse tran-
scribed RNA, 7.5 pmol of each gene-speciﬁc primer (Table 1) and
IQ™ SybrGreen Supermix (Biorad) in a ﬁnal 25 lL reaction volume
was analyzed by quantitative PCR in a MyIQ single color real time
PCR detection system (BioRad). Following an initial hot start for
3 min, 40 cycles were run with a denaturation step at 95 C for
20 s, an annealing step at 63 C for 30 s and an elongation step at
72 C for 30 s.
2.6. Immunocytochemistry
For the immunocytochemical detection of ABC-transporters in
the GL-1 and GL-40 cells, cytospin smears were prepared by plac-
ing 5  105 cells in culture medium into a cytology funnel with
pre-attached ﬁltercard (Biomedical Polymers Inc, Gardner (MA),
USA) that was ﬁxed with a funnel clip onto a polysine microscope
slide (Menzel-Gläser, Braunschweig, Germany) and centrifuged at
650 rpm for 10 min in a cytospin centrifuge (Thermo Scientiﬁc™
Cytospin™ 4 Cytocentrifuge, Thermo Shandon Limited, Runcorn,
UK). The freshly prepared cytospin preparations (1 106 cells/slide)
were air dried, followed by a 3 min ﬁxation step in acetone. After
rehydration in phosphate-buffered saline (PBS) and incubation
with 10% swine serum in PBS (20 min), endogenous peroxidase
activity was blocked with 0.3% H2O2 in methanol (Cell Marque,
Rocklin, CA, USA) for 10 min. Slides were then incubated
with mouse antibodies directed against human P-gp (Van der
Heyden et al., 2011) (C494, Alexis Switzerland), MRP1 (Scheffer
Table 1
Primer details.
Canine gene GenBank Forward primer Reverse primer Product size Ta (C)
Abcb1 (P-gp) NM_001003215 CTATGCCAAAGCCAAAGTATC GAGGGCTGTAGCTGTCAATC 80 57.5
Abcc1 (MRP1) NM_001002971 CGTGACCGTCGACAAGAACA CACGATGCTGATGACCA 118 60.9
Abcg2 (BCRP) NM_001048021 GGTATCCATAGCAACTCTCCTCA GCAAAGCCGCATAACCAT 146 60.0
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BCRP (Maliepaard et al., 2001) (BXP-21, Abcam, UK) for 1 h at room
temperature. Antibody binding was detected by polyvalent biotin-
ylated serum, HRP-labeled streptavidin and diaminobenzidine as a
chromogen (Cell Marque, Rocklin, CA, USA). Following a 10-min
wash in aqua dest, counterstaining was performed with hematoxy-
line solution according to Mayer (Sigma, St Louis, MO, USA) for
3 min, followed by a 2-min washing step in aqua dest.
2.7. Functional studies with ﬂuorescent transporter substrates and
selective inhibitors
Functional studies were performed using the typical ﬂuorescent
substrate-inhibitor combinations Rh123-PSC833 for assessing
P-gp, CFDA-MK571 for MRP, and PhA-Ko143 for BCRP function
(Allen et al., 2002; Dogan et al., 2004; Schleis et al., 2008). All
experiments with GL-40 cells were performed with cells that had
been incubated for one passage without doxorubicin. Before the
GL-1 and GL-40 cells were used in experiments with ﬂuorescent
dyes, cell viability was assessed with trypan blue exclusion and cell
numbers were counted in a hematocytometer. A total of 5  105
viable cells per sample were plated into 96-well plates. In the
transport studies, culture mediumwas replaced by Hanks Balanced
Salt Solution (HBSS) without Ca2+, Mg2+ and phenol red and with
1000 mg/L glucose (Gibco, Grand Island, NY, USA). All chemicals
were dissolved in DMSO as 1.000 stock solutions resulting in a
ﬁnal concentration of DMSO of 0.1% for all samples.
P-gp and BCRP transporter activity were assessed in an efﬂux
assay. A total of 5  105 viable cells per sample were plated into
96-well plates and after centrifugation (50g, 3 min) culture med-
ium was replaced by HBSS containing Rh123 (4 lmol/L) or PhA
(0.1–1 lmol/L) and cells were incubated for 30 min (37 C, 5%
CO2). Following this loading, cells were washed twice in PBS
(Gibco, Grand Island, NY, USA) by centrifugation and the cell
pellets were re-suspended in HBSS containing a concentration
range of PSC833 or Ko143 as indicated in the results section.
Incubation was continued for a further two hours, after which
cell-suspensions were pelleted by centrifugation (4 C) and the
medium was replaced by dye-free HBSS (4 C). These cell suspen-
sions were collected and transferred into FACS-tubes and placed
on ice until FACS analysis.
P-gp and BCRP transporter activity were also assessed in an
uptake study. MRP activity was assessed only in a CFDA uptake
study. In contrast to Rh123 and PhA, CFDA requires cleavage by
intracellular esterases to generate CF, the ﬂuorescent product mea-
sured in the uptake study. In order to demonstrate substrate and
inhibitor speciﬁcity, a concentration series of the P-gp inhibitor
PSC833 and the MRP inhibitor MK571 were tested in combination
with Rh123 and CFDA. For the ﬂuorescent dye accumulation
assays, culture medium was replaced by HBSS containing the ﬂuo-
rescent transporter substrate dye and an inhibitor. After 30 min of
incubation (37 C, 5% CO2), culture medium was replaced by PBS
(4 C) and the cell suspensions were transferred into FACS-tubes
and placed on ice until FACS analysis.
A ﬂow cytometer (FACS Calibur, Biorad, The Netherlands)
equipped with an argon 488 nm laser was used to analyze the
samples. Cell-associated ﬂuorescence of Rh123 and CF was
measured using a 530-nm bandpass ﬁlter and cell-associated PhAﬂuorescence was measured using a 610-nm longpass ﬁlter. The
samples were gated on forward scatter versus side scatter to
exclude clumps and cell debris. Data were collected for a minimum
of 10,000 gated events per sample.
2.8. FACS data analysis
FACS data represent the geometric mean cell-associated ﬂuo-
rescence intensity and are reported in Relative Fluorescence Units
(RFU). Changes in the cellular accumulation (Rh123, CF or PhA) by
the inhibitors were presented as RFU. Efﬂux (Rh123, PhA) was cal-
culated according to Eq. (1) and expressed as a percentage with
one hundred percent efﬂux meaning that after two hours of incu-
bation no ﬂuorescence was measured within the cells and zero
percent efﬂux meaning that all ﬂuorescence was retained within
the cells due to efﬂux inhibition.
Efflux ¼ ½ðFL0  FLBÞ  ðFL120  FLBÞ=ðFL0  FLBÞ x 100% ð1Þ
FL0 is the Fluorescence intensity at t = 0 min, FLB is the Fluorescence
intensity of the background, and FL120 is the Fluorescence intensity
of the samples at t = 120 min.
2.9. Glucocorticoid receptor assay
The presence of a functional glucocorticoid receptor was
assessed in both GL-1 and GL-40 cells using a luciferase assay as
previously described by Gracanin et al., 2012. In short, GL-cells
(8  105 cells/well) were seeded in 24-well plates and transfected
using per well 2 lL Lipofectamine 2000 (Invitrogen, Bleiswijk,
the Netherlands), 800 ng of Mouse Mammary Tumor Virus
(MMTV)-luciferase containing a glucocorticoid receptor-
responsive reporter, and 0.3 ng of human b-actin-promoter
renilla as an internal control. Following transfection the cells were
left to recover for 24 h and then incubated with prednisolone
(0.1 lmol/L) for 24 h. Fireﬂy and renilla luciferase activities were
subsequently quantiﬁed using a Dual-Luciferase Assay System
(Promega, Leiden, the Netherlands) in a Centro LB 960 lumino-
meter (Berthold Technologies, Vilvoorde, Belgium). The canine
mammary cell line CNMm was used as a positive control.
2.10. Effect of prednisolone on ABC-transporter expression
The cells were incubated with a concentration range of prednis-
olone for 3, 6 and 24 h in cell culture medium (RPMI 1640). At the
time of sampling, the cells were harvested by centrifugation, med-
ium was discarded and the cell pellet was lysed in Promega lysis
buffer. RNA isolation, cDNA synthesis and quantitative PCR
analysis were performed as described above. Results are reported
as Relative Expression that was calculated according to Eq. (2).
Relative Expression ¼ 2 ^ ðCtmean  CtsampleÞ ð2Þ
Ctmean is the mean Ct value at t = 0 h for each ABC transporter for
GL-1 or GL-40, and Ctsample is the mean Ct value at t = 3, 6 or 24 h
for each ABC transporter for GL-1 or GL-40.
2.11. Statistical analysis
All experiments were repeated independently for three times.
Differences in accumulation or efﬂux of ﬂuorescent dyes in the
Table 2
Drug sensitivity represented by IC50-values (nM; mean with 95% conﬁdence intervals)
in the GL-1 and GL-40 cells for doxorubicin and vincristine and the effect of PSC833
(1 M).
Drug PSC833 GL-1 GL-40
Doxorubicin (nM)  17.2 (15.0–19.5) 115 (109–120)
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lyzed for statistic signiﬁcance using the One-Way ANOVA with
Dunnett multiple comparison post hoc test. The level of signiﬁ-
cance was set at P < 0.05 and signiﬁcant differences are mentioned
in the text. All statistical analyses were performed using Graph Pad
Prism software (San Diego, California, USA).+ 13.3 (10.7–16.6) 15.8 (15.3–16.6)
Vincristine (nM)  0.54 (0.52–0.57) 21.4 (16.9–27.2)
+ 0.32 (0.31–0.33) 0.31 (0.31–0.32)3. Results
3.1. GL-40. cells are resistant to doxorubicin and vincristine, but not
prednisolone
The sub-cell line GL-40 was selected from GL-1 cells through
intermittent incubation with gradually increasing concentrations
of doxorubicin over a 6-month period and resulted with an
increase in IC50-doxorubicin from 17.2 nmol/L for GL-1 cells to
115 nmol/L for GL-40 cells. GL-40 cell showed resistance to vincris-
tine with an IC50-vincristine 0.54 nmol/L for GL-1 cells and
21.4 nmol/L for GL-40 cells (Fig. 1, Table 2). Prednisolone caused
a mild (35%), but signiﬁcant decrease in cell proliferation that
was similar in both GL cell lines (Fig. 2).Fig. 2. Inhibition of cell proliferation by prednisolone in GL-1 and GL-40 cells. Data
are presented as mean ± SD of three independent experiments.3.2. Immunocytochemistry of ABC-transporters P-gp, MRP1 and BCRP
P-gp expression was detected using the monoclonal antibody
C494 and appeared more intense in GL-40 than GL-1 cells
(Fig. 3). Using the monoclonal antibody M2III-6, MRP1 expression
was demonstrated in both cell lines, but appeared more intense
in GL-1 cells (Fig. 3). BCRP expression, using the monoclonal anti-
body BXP-21, was similar in both cell lines (Fig. 3).Fig. 1. Inhibition of cell proliferation by doxorubicin (A and B) and vincristine (C and
presented as mean ± SD of three independent experiments.3.3. mRNA expression of the ABC-transporters P-gp, MRP1 and BCRP
P-gp mRNA expression was signiﬁcantly lower in GL-1 cells
(CtP 35) than in GL-40 cells (Ct = 22), indicating an approximatelyD) and the effect of PSC833 on drug sensitivity in GL-1 and GL-40 cells. Data are
Fig. 3. Microscopic photographs of GL-1 (top row) and GL-40 (lower row) cells stained with May-Grünwald Giemsa (MGG) and immunocytochemical staining for P-gp, MRP1
and BCRP (columns).
Fig. 5. Efﬂux of the P-gp substrate rhodamine 123 by GL1 and GL-40 cells after 2 h
of incubation in dye-free medium with increasing concentrations of PSC833. Data
are presented as mean ± SD of three independent experiments.
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expression were both detected (Ct values of 22 and 23 respec-
tively), but similar in both GL-cell lines.
3.4. Functional studies for P-gp, MRP and BCRP
3.4.1. Rhodamine 123 as a probe dye for Pgp function
Rhodamine123 efﬂux from the GL-40 cells was approximately 4
times higher compared to the GL-1 cells (Fig. 4) and the
P-gp-inhibitor PSC833 decreased Rh123 efﬂux in a concentration
dependent fashion in the GL-40 cells (IC50 0.05 lmol/L), but not
in the GL-1 cells (Fig. 5).
Rhodamine 123 accumulation was signiﬁcantly lower in GL-40
compared to GL-1 cells and PSC833 caused a concentration depen-
dent increase in Rh123 accumulation in the GL-40, but not in the
GL-1 cells (Fig. 6). Only higher concentrations of MK571 (5 and
25 lmol/L) signiﬁcantly increased Rh123 accumulation in the
GL-40, but not the GL-1 cells (Fig. 6).
3.4.2. CFDA as a probe dye for MRP-transporters
Cellular accumulation of CF following incubation with CFDA
(1 lmol/L) was higher in the GL-40 cells compared to the GL-1 cells
and MK571 increased CF accumulation in a concentration depen-
dent way in both GL cell lines (Fig. 7). The highest PSC833 concen-
tration tested (1 lmol/L) resulted in a minor, but signiﬁcant,
increase in CF accumulation in the GL-1 cells at (Fig. 7).
3.4.3. Pheophorbide A as a probe dye for BCRP
PhA was tested at a concentration range from 0.1 to 1 lmol/L in
combination with the BCRP inhibitor Ko143 at 1 lmol/L. PhA efﬂuxFig. 4. P-gp mRNA expression, measured by qPCR (left), and P-gp function, measured b
presented as mean ± SD of three independent experiments.(%) was similar in both GL-1 and GL-40 cells and decreased with
increasing concentrations of PhA. Incubation with Ko143 had no
effect on PhA efﬂux (Fig. 8). Cellular accumulation of PhA was com-
parable for both the GL-1 and GL-40 cell lines (Fig. 8), and Ko143
had no signiﬁcant effect on the cellular PhA accumulation in either
cell-line.3.5. Doxorubicin and vincristine resistance in GL-40 cells is reversed by
PSC833
PSC833 (1 lmol/L) restored GL-40’s sensitivity to the antiprolif-
erative effects of doxorubicin and vincristine to levels comparabley rhodamine123 efﬂux (right), in the GL-1 and GL-40 cells, respectively. Data are
Fig. 6. Cellular rhodamine 123 accumulation after 30 min of incubation with Rhodamine 123 (4 lmol/L) in combination with increasing concentrations of PSC833 (A) or
MK571 (B). Data are presented as mean ± SD of three independent experiments.
Fig. 7. Cellular 5(6)-carboxyﬂuorescein accumulation after 30 min of incubation with 5(6)-carboxyﬂuorescein diacetate (1 lmol/L) and increasing concentrations of PSC833
(A) or MK571 (B). Data are presented as mean ± SD of three independent experiments.
Fig. 8. Efﬂux of Pheophorbide A (0.5 lmol/L) by GL1 and GL-40 cells after 30 min of incubation in dye-free medium in the absence or presence of Ko143 (A) and cellular
Pheophorbide A accumulation in GL1 and GL-40 cells after 30 min of incubation with Pheophorbide A in the absence or presence of Ko143 (B). Data are from a representative
experiment and presented as mean ± SD.
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antiproliferative effect in both GL cell lines (Fig. 1).
3.6. GL-cells have a functional glucocorticoid-receptor, but
prednisolone fails to induce P-gp, MRP1 or BCRP expression
Following transfection of CNMm, GL-1, and GL-40 cells with
MMTV-luc, prednisolone (0.1 lM) caused a, respectively, 6-, 4-,
and 2.6-fold increase in luciferase-activity conﬁrming the presence
of active glucocorticoid receptors in both cell-lines.
Short-term incubation (3, 6, 24 h) of both GL-1 and GL-40 cells
with prednisolone did not signiﬁcantly change the mRNA expres-
sion of P-gp, MRP1, and BCRP (Fig. 9). The low levels of P-gp mRNAexpression in the GL-1 cells (CtP 35), resulted in a large variation
in relative expression results.
4. Discussion
Selection for doxorubicin resistance by exposing the canine
B-cell lymphoid leukemia cell line GL-1 (Nakaichi et al., 1996) to
gradually increasing concentrations of doxorubicin led to the
GL-40 sub-cell line that was six times more resistant to doxorubi-
cin and showed cross-resistance to the structurally and mechanis-
tically unrelated cytotoxic agent vincristine. The observed DR
corresponded with an increased P-gp expression (mRNA and
immunocytochemistry) and transport capacity for the P-gp model
Fig. 9. The relative mRNA expression of P-gp, MRP1 and BCRP in the GL-1 and GL-40 cells following incubation with prednisolone (lmol/L) for 0, 3, 6, and 24 h. Data are
presented as mean ± SD of three independent experiments.
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reversed with the prototypical P-gp inhibitor PSC833. Therefore,
it is concluded that P-gp causes multi-drug resistance in the
GL-40 sub-cell line, which is in line with previous in vitro studies
(Uozurmi et al., 2005; Matsuura et al., 2007). Furthermore these
results indicate that in the dog, as in humans (Ambudkar et al.,
1999), doxorubicin and vincristine are both P-gp substrates. Given
the fact that P-gp expression is more prevalent in dogs with
relapsed and DR cL (Bergman et al., 1996; Lee et al., 1996; Page
et al., 2000), GL-40 cells represent a suitable in vitro model for
studying DR in canine lymphoid neoplasia.
Induction of DR through incubation with increasing concentra-
tions of a cytostatic agent, the method used in the current study,
has a tendency to preferentially select for P-gp overexpression as
the major DR-mechanism and might not necessarily reﬂect
in vivo DR, which can be conveyed through both other efﬂux–
transporters, as well as other mechanisms (Calcagno and
Ambudkar, 2010). For example, besides increased P-gp expression,
changes in cellular survival signaling cascades, resistance to
apoptosis and upregulation of antioxidant defense enzymes
(McCubrey et al., 2006; Tome et al., 2012) have been shown toresult in DR and these mechanisms might also have contributed
to GL-40’s DR phenotype.
Other ABC-transporters implicated in DR to cytostatic drugs in
humans include MRP1 and BCRP. The canine orthologs of both
these transporters have been evaluated in transfected cell lines
and have associated MRP1 with resistance to vincristine, but not
doxorubicin (Ma et al., 2002) and BCRP with resistance to doxoru-
bicin (Honscha et al., 2009). In the GL-40 cells the level of MRP1
mRNA expression was similar to that of the parental GL-1 cells,
although the less intense immunoreactivity and the higher CF
retention in the GL-40 cells suggest a reduced MRP1 protein-
expression and function. BCRP expression (mRNA, immunocyto-
chemistry) and function (PhA transport) seemed low and equal
for both GL cell-lines. Therefore, it can be assumed that neither
MRP1, nor BCRP are a cause for GL-40’s observed DR.
Prednisolone had a mild and equal antiproliferative effect on
both GL-1 and GL-40 cells. The absence of prednisolone resistance
in the GL-40 cells is not consistent with the assumption that pred-
nisolone is a P-gp substrate and stands in contrast with human
data (Crowe and Tan, 2012) and a canine in vivo study (Van der
Heyden et al., 2012). The absence of a functional glucocorticoid
M. Zandvliet et al. / Toxicology in Vitro 28 (2014) 1498–1506 1505receptor would explain this ﬁnding, but is rejected since a
luciferase assay demonstrated activation of glucocorticoid receptor
response elements following exposure to prednisolone in both
GL cell lines. Alternative mechanisms for this unexpected
glucocorticoid resistance would include down-stream effects like
resistance to glucocorticoid-induced apoptosis (Schlossmacher
et al., 2011). This observation, as well as the cause for the lower
luciferase-activity activity in the GL-40 cells, requires further
investigation. Furthermore, prednisolone failed to induce expres-
sion of P-gp, MRP1 and BCRP mRNA in both GL-1 and GL-40 cells.
Based on these data, prednisolone appears neither a substrate for,
nor an inducer of P-gp in canine lymphoid cells, which makes the
assumption that prednisolone treatment leads to DR through
induction of P-gp overexpression unlikely.
In this study PSC833 and MK571 were used as inhibitors for
P-gp and MRPs respectively (Dogan et al., 2004; Schleis et al.,
2008). Our data show that, in the concentration range tested,
PSC833 is a selective inhibitor of canine P-gp with only a mild,
and functionally not relevant, inhibition of MRP’s at the highest
concentration tested. MK571, however, has a comparable effect
on Rh123 and CF accumulation in both cell lines suggesting com-
parable inhibitory potencies towards P-gp and MRP’s, as was pre-
viously shown for the human homologue transporters (Matsson
et al., 2009). The combination of PhA with Ko143 at 1 lmol/L, a
concentration expected to fully block BCRP (Allen et al., 2002)
was tested, but the differences in PhA accumulation between the
two GL-cell lines and the effect of Ko143 on PhA accumulation
were small and not statistically different. Further studies are
needed to demonstrate their use for assessing canine BCRP function.
Because of the common observation of elevated levels of P-gp in
multidrug resistant human cancers, signiﬁcant effort has been
spent on developing potent and selective compounds that can
modulate P-gp function without undesirable toxicity like PSC833
(Darby et al., 2011). The highly increased Rh123 efﬂux and P-gp
expression in the GL-40 cells makes these cells a good model for
studying interactions of these compounds with canine P-gp. Next
to P-gp inhibition, PSC833 is also capable of inducing apoptosis
in human leukemia T-cells by increasing cellular ceramide levels
(Azare et al., 2001). An inhibitory effect of PSC833 on lymphoid cell
proliferation was also observed in the current study, which appears
independent of P-gp function since both GL-1 and GL-40 cells
appeared equally sensitive.
In conclusion, P-gp appears to play an important role in multi-
drug resistance in canine lymphoid neoplasia, and we present a
canine (lymphoid) cell model that allows for the study of multi-
drug resistance in vitro as well as the effect of MDR-modulators
thereon.
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